Ready to explore hormone therapy
By choosing MedBridges medically supervised GLP-1 program, you benefit from evidence-based care, a personalized treatment plan, and access to the latest advancements in obesity medicine
Importantly, most GLP-1 receptor agonists carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
AOD-9604 is not FDA-approved, so a clinician will evaluate the reaction without label-based guidance
Injectable research studies have similarly reported low rates of adverse events, though this should not be read as a clinical endorsement for any particular use
For those exploring alternatives, switching from tirzepatide to semaglutide or vice versa sometimes restarts progress